Grant: A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarcevar) in combination with OSI 906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

  • Basic View
  • XML View
Project Title
A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarcevar) in combination with OSI 906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
 
Principal Investigator Ho, James Chung Man (Principal investigator)
Co-Investigator(s) Lam, Chi Leung David (Co-Investigator)
Dr Wong Matthew (Co-Investigator)
Dr Lam Jamie (Co-Investigator)
Funding Year
2010/2011
 
Amount
606762
 
Panel Medicine
Start Date
01-04-2011
 
Expected Completion
30-09-2013
 
Status
On-going
 
Keywords non-small cell lung cancer
Grant Type/Funding Scheme Pharmaceutical Industry - General Award
Duration
30
 
[Coming Soon]